Interpreting large-scale single-cell transcriptomic data remains a major challenge for understanding disease mechanisms. Recent single-cell foundation models learn rich representations of gene relationships across millions of cells, yet methods for translating these embeddings into biologically interpretable gene networks remain limited. Here we present scGENet, a computational framework that constructs context-specific gene interaction networks from foundation model–derived gene embeddings. By fine-tuning pretrained models on transcriptomic data from human midbrain organoids, scGENet generates transcriptome-scale gene modules that capture biologically meaningful cellular programs. Benchmarking across multiple foundation models demonstrates that networks derived from a fine-tuned scGPT brain model show the highest concordance with curated neuronal pathways, Parkinson’s disease (PD) genetic risk loci, and independent patient-derived transcriptional signatures. Applying this framework to human iPSC-derived PD midbrain organoids reveals transcriptional modules associated with neuronal differentiation, synaptic signaling, and cell-cycle regulation. Single-nucleus RNA sequencing further links these programs to altered cellular composition, including reduced dopaminergic neurons, expansion of radial glia–like progenitors, and a dopaminergic neuron subtype expressing SNCA and VGLUT2. Integration with independent human substantia nigra datasets identifies a conserved neurogenic program disrupted across genetic and idiopathic PD. Together, these results establish a generalizable strategy for extracting interpretable gene networks from single-cell foundation models, enabling systematic discovery of disease-relevant molecular programs across diverse tissues and datasets.
Jun Yin, Maya L. Gosztyla, Birkan Gokbag et al.· bioRxiv· 0 citations
Parkinson's disease (PD) poses a major unmet therapeutic challenge, with most drug candidates failing in clinical translation despite promising animal model data. Human induced pluripotent stem cell-derived midbrain organoids recapitulate key PD pathological hallmarks - including dopaminergic neuron loss, α-synuclein aggregation, and neuroinflammation - in a genetically defined, human-specific context. This review summarizes drug screening studies in midbrain organoids across genetic, toxin-based, and α-synuclein preformed fibril models. We highlight therapeutic interventions that rescue PD phenotypes, compare organoid and animal model systems, and discuss the personalized medicine potential of patient-derived organoids. We also critically assess current limitations and outline how artificial intelligence integration and assembloid platforms are advancing organoid-based drug discovery towards regulatory acceptance.
Alise Zagare, J. Jarazo, J. Schwamborn· Drug Discovery Today· 0 citations
Data show that LRRK2-G2019S impairs astrocyte specification and predisposes to a senescent phenotype, which contributes to the acquisition of a senescent-like phenotype in Parkinson’s disease patients.
Lisa M. Smits, S. Magni, K. Grzyb et al.· npj Parkinson's Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.